文献速递骨软组织肉瘤与黑色素瘤

Tebentafusp与纳武利尤单抗联合伊匹木单抗一线治疗转移性葡萄膜黑色素瘤的总生存比较:倾向评分加权分析

Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis.
PubMed 文献 · Ann Oncol · 2023-12-02

在未经治疗的转移性葡萄膜黑色素瘤中,采用倾向评分逆概率加权法比较Tebentafusp(IMCgp100-202试验)与纳武利尤单抗联合伊匹木单抗(GEM1402试验)的总生存,加权后Tebentafusp组1年OS为73%,N+I组为50%,HR 0.52(95%CI 0.35-0.78),支持Tebentafusp作为HLA-A*02:01阳性成人患者的标准治疗。

要点

  • IPTW加权后Tebentafusp较N+I显著改善OS:HR 0.52(95%CI 0.35-0.78),1年OS 73% vs 50%。
  • 敏感性分析中所有IPTW的HR均≤0.61,一致支持Tebentafusp的OS优势。
  • 帕博利珠单抗与N+I的OS无显著差异:HR 0.72(95%CI 0.50-1.06)。

核心结论

  • 倾向评分分析显示Tebentafusp较纳武利尤单抗联合伊匹木单抗具有相似的OS获益,进一步支持Tebentafusp作为未经治疗的HLA-A*02:01阳性成人转移性葡萄膜黑色素瘤患者的标准治疗。

研究设计与样本

  • 采用倾向评分逆概率治疗加权(IPTW)比较IMCgp100-202(随机III期,N=378)中Tebentafusp或帕博利珠单抗与GEM1402(单臂,N=52)中纳武利尤单抗联合伊匹木单抗的OS。
  • IPTW平衡了年龄、性别、基线乳酸脱氢酶、基线碱性磷酸酶、疾病部位、Eastern Cooperative Oncology Group状态及原发诊断至转移时间。
  • 主要IPTW分析纳入IMCgp100-202中随机分配至Tebentafusp的252例中的240例及GEM-1402中接受N+I治疗的52例中的45例。

主要发现

  • IPTW调整后OS favoring Tebentafusp,HR 0.52(95%CI 0.35-0.78);1年OS为Tebentafusp组73% vs N+I组50%。
  • 敏感性分析显示Tebentafusp的OS优势一致,所有IPTW的HR均≤0.61。
  • 帕博利珠单抗与N+I的IPTW分析显示OS无显著差异(HR 0.72;95%CI 0.50-1.06)。

临床怎么用

  • 作者认为这些数据进一步支持Tebentafusp作为未经治疗的HLA-A*02:01阳性成人转移性葡萄膜黑色素瘤患者的标准治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tebentafusp demonstrated a superior overall survival (OS) benefit [hazard ratio (HR) 0.51] compared to investigator's choice (82% pembrolizumab) in a randomized, phase III trial (IMCgp100-202; N = 378) in untreated metastatic uveal melanoma (mUM). The 1-year OS rates for tebentafusp and pembrolizumab were 73% and 59%, respectively. In the single-arm GEM1402 (N = 52), the 1-year OS rate for nivolumab plus ipilimumab (N+I) in mUM was 52%. Due to limitations in conducting randomized trials in mUM, we compared OS on tebentafusp or pembrolizumab (IMCgp100-202) to N+I (GEM1402) in untreated mUM using propensity scoring methods. PATIENTS AND METHODS: Analyses were adjusted using propensity score-based inverse probability of treatment weighting (IPTW), balancing age, sex, baseline lactate dehydrogenase (LDH), baseline alkaline phosphatase, disease location, Eastern Cooperative Oncology Group status, and time from primary diagnosis to metastasis. OS was assessed using IPT-weighted Kaplan-Meier and Cox proportional hazard models. Sensitivity analyses using alternative missing data and weights methods were conducted. RESULTS: The primary IPTW analysis included 240 of 252 patients randomized to tebentafusp from IMCgp100-202 and 45 of 52 N+I-treated patients from GEM-1402. Key baseline covariates, including LDH, were generally well balanced before weighting. The IPTW-adjusted OS favored tebentafusp, HR 0.52 [95% confidence interval (CI) 0.35-0.78]; 1-year OS was 73% for tebentafusp versus 50% for N+I. Sensitivity analyses showed consistent superior OS for tebentafusp with all IPTW HRs ≤0.61. IPTW analysis of pembrolizumab versus N+I showed no significant difference in OS (HR 0.72; 95% CI 0.50-1.06). CONCLUSIONS: Tebentafusp was previously shown to provide an OS benefit compared to checkpoint inhibitors or chemotherapy in untreated mUM. Propensity score analysis demonstrated a similar OS benefit for tebentafusp compared with N+I. These data further support tebentafusp as the standard of care in previously untreated human leukocyte antigen (HLA)-A∗02:01+ adult patients with mUM.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Piulats JM, Watkins C, Costa-García M, et al. Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis. Ann Oncol. 2023. PMID: 38048850. doi:10.1016/j.annonc.2023.11.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。